Glenmark Pharmaceuticals has announced an update to its list of officials authorized to determine the materiality of events and information for disclosures. This change was approved by the Board of Directors on July 31, 2026, and aligns with SEBI’s Listing Obligations and Disclosure Requirements. The updated list includes key management personnel responsible for ensuring timely and accurate communication with stock exchanges.
Glenmark Pharmaceuticals Board Approves Policy Amendments
Glenmark Pharmaceuticals announced that its Board of Directors, during a meeting held on Friday, July 31, 2026, at 4:00 p.m., approved amendments to the Company’s Policy on Determination of Materiality for Disclosures. This strategic decision underscores the company’s commitment to robust corporate governance and transparent communication with its stakeholders.
Authorized Officials for Disclosure
Further to the policy update, the company has also designated specific officials authorized to determine the materiality of events or information and to make necessary disclosures to the stock exchanges, as per the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The authorized personnel are:
- Mr. Glenn Saldanha, Chairman & Managing Director
- Mrs. Cherylann Pinto, Executive Director – Corporate Services
- Mr. Anurag Mantri, Executive Director & Global Chief Financial Officer
- Ms. Rashmi Khandelwal, Company Secretary & Compliance Officer
These individuals are responsible for ensuring compliance with regulatory requirements regarding timely and accurate disclosures, thereby maintaining investor confidence and market integrity.
Source: BSE
